AHFS Class:

10:00 Antineoplastic Agents

Generic Name

• Atezolizumab (CAS Registry Number: 1380723-44-3)

Atezolizumab is available as a 60-mg/mL concentrate for injection in 14- and 20-mL preservative-free, single-dose vials.³⁸⁷¹ Each 14-mL vial contains atezolizumab 840 mg with glacial acetic acid 11.5 mg, L-histidine 43.4 mg, polysorbate 20 5.6 mg, and sucrose 575.1 mg.³⁸⁷¹ Each 20-mL vial contains atezolizumab 1200 mg with glacial acetic acid 16.5 mg, L-histidine 62 mg, polysorbate 20 8 mg, and sucrose 821.6 mg.³⁸⁷¹

The concentrate must be diluted prior to administration.³⁸⁷¹ To prepare the drug for intravenous infusion, the appropriate dose of the concentrate should be withdrawn from the vial and diluted in sodium chloride 0.9% to a final atezolizumab concentration between 3.2 and 16.8 mg/mL.³⁸⁷¹ The solution should be mixed by gentle inversion and should not be shaken.³⁸⁷¹ Infusion containers composed of polyvinyl chloride (PVC), polyethylene, or polyolefin may be used.³⁸⁷¹ Any unused portion remaining in vials should be discarded.³⁸⁷¹

pH

5.8.³⁸⁷¹

Trade Name(s)

Tecentriq

Atezolizumab is administered only by intravenous infusion after dilution in sodium chloride 0.9%.³⁸⁷¹ The drug should not be administered by intravenous push or bolus injection.³⁸⁷¹ Diluted solutions for infusion may be administered through a 0.2- to 0.22-µm low protein-binding inline filter.³⁸⁷¹

The first infusion should be administered over 60 minutes.³⁸⁷¹ If the first infusion is tolerated, subsequent infusions may administered over 30 minutes.³⁸⁷¹

Intact vials of atezolizumab should be stored at 2 to 8°C in the original carton to protect from light and should not be shaken or frozen.³⁸⁷¹ The concentrate for injection is a colorless to slightly yellow solution.³⁸⁷¹ Vials should be visually inspected for particulate matter and discoloration prior to use; discard the solution if it is cloudy, discolored, or contains visible particles.³⁸⁷¹

The manufacturer states diluted solutions may be stored for not more than 6 hours at room temperature, including administration time, or 24 hours at 2 to 8°C.³⁸⁷¹ Diluted solutions should not be shaken or frozen.³⁸⁷¹

Sorption

The manufacturer states that infusion containers composed of polyvinyl chloride (PVC), polyethylene, or polyolefin may be used for preparation of atezolizumab.³⁸⁷¹

Filtration

The manufacturer states that diluted solutions for infusion may be administered through a 0.2- to 0.22-µm low protein-binding inline filter.³⁸⁷¹

Solution Compatibility

For a list of references cited in the text of this monograph, search the monograph titled References.

ASHP^® Injectable Drug Information^TM. Selected Revisions March 23, 2023. © Copyright, 2025. American Society of Health-System Pharmacists^®, 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.